In addition, chronic lymphocytic leukemia cells with ATM mutations have shown increased resistance to doxorubicin, likely due to their inability to activate the pro-apoptotic p53 pathway following drug administration 39. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.